Navigation Links
Data Analysis Reinforces the Safety Profile of Levemir(R)
Date:10/20/2009

PRINCETON, N.J., Oct. 20 /PRNewswire-FirstCall/ -- A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin(1,2).

The analysis conducted by Novo Nordisk assessed the relative risk of a cancer diagnosis during clinical treatment with Levemir®. It included approximately 9,000 patients (approximately 5,200 taking Levemir®) in 21 randomized controlled trials and compared the incidence of cancer in patients treated with Levemir® with that of patients treated with either human insulin (NPH insulin) or insulin glargine.

The data revealed that treatment with Levemir® was associated with a statistically significantly lower incidence of cancer than with NPH insulin treatment (0.36 events per 100 patient years in the Levemir® group vs. 0.92 events in the NPH insulin group; p<0.05).

The incidence of cancer during Levemir® treatment was also lower than that seen during treatment with insulin glargine, but this difference was not statistically significant (0.87 events per 100 patient years in the Levemir® group vs. 1.27 events in the insulin glargine group; p>0.05)(3).

"We have designed Levemir® with all aspects of safety for the patient in mind and these data are in line with what we would expect," said Dr. Alan Moses, Novo Nordisk Vice President and Chief Medical Officer. "Physicians, health care providers and patients can continue to feel confident in using Levemir® to effectively treat type 1 and type 2 diabetes."

The analysis was performed in response to the Diabetologia June publication of four registry studies(4). Those studies, while inconclusive due
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors
2. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
3. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
4. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
5. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
6. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
7. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
8. SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts
9. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
10. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
11. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Pa., Oct. 29 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today ... Credit Suisse Healthcare Conference to be held November 10-12, 2010 ... Fickenscher, Chief Financial Officer, is scheduled to present an overview ... ET on Thursday, November 11, 2010. To listen ...
... Calif., Oct. 28 VIVUS, Inc. (Nasdaq: ... Response Letter (CRL) from the U.S. Food and Drug ... the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The ... the NDA cannot be approved in its present form. ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Wrigley told the jurors that Dru Sjodin, 22, struggled for ... Rodriguez Jr. was the man responsible for her death.// ... has pleaded not guilty to a charge of abduction resulting ... of North Dakota. According to prosecutors, death penalty will be ...
... are hairier than others may have been discovered, according to ... embryonic skin cells will form into hair follicles, deciding the ... the University of Manchester. ,This study on mice ... -- a range of conditions in which skin cells fail ...
... be wary of the so-called stem cell wonder cures that ... tested.// ,The health experts had yesterday in a ... a world leader in stem cell research, but cautioned that ... cosmetic skin treatment were yet to be proven, and could ...
... from Johns Hopkins and made available on the World Wide ... to cilia operations in the body. // ,The researchers ... structures on the surface of cells called cilia as such ... 'orphaned diseases' all have links associated with the tiny, hair-like ...
... Paisley and the Raigmore in Inverness do not maintain hygiene ... Scotland. ,The study categorized hospitals by traffic light ... the set standards, amber for hospitals in the 70% and ... ERI, the rate was 84.1%, while Raigmore scored 83.1% and ...
... Institute of Virology in Pune declared Tuesday there is no ... from here in south Gujarat.// ,Additional director of ... Surat city, and not even a single sample contained Hantavirus." ... not yet clarified why two persons had died last week. ...
Cached Medicine News:Health News:The fate of an accused in a murder case to be decided 2Health News:Scientists In UK Issue A Caution Over Untested Stem Cell Treatments 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: